Group 1 - The major shareholder, Zhangjiang Biopharmaceutical Base Development Co., Ltd., holds 11,020,753 shares, accounting for 7.82% of the total share capital of the company [1] - Zhangjiang Biopharmaceutical Base plans to reduce its holdings by up to 1,409,796 shares, which is no more than 1.00% of the total share capital, within three months after the announcement [1] - The reduction will be executed through centralized bidding, and the selling price will be determined by market conditions [1][2] Group 2 - The major shareholder has made commitments regarding the holding period and reduction methods, including a lock-up period of 12 months for shares held before the IPO and 36 months for shares obtained through capital increase [2][3] - The reduction plan is consistent with previous commitments made by the major shareholder [4] - The company confirms that the reduction will not lead to a change in control and will not significantly impact the company's ongoing operations [5]
上海益诺思生物技术股份有限公司股东减持股份计划公告